S.M. Mansour Haeryfar

Dr. S.M. Mansour Haeryfar

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BRBertrand Routy
Bertrand Routy
JLJohn G. Lenehan
John G. Lenehan
WMWilson H. Miller
Wilson H. Miller
RJRahima Jamal
Rahima Jamal
MMMeriem Messaoudene
Meriem Messaoudene
SVSaman Maleki Vareki
Saman Maleki Vareki

12 April 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
BSBradly Shrum
Bradly Shrum
RARam V Anantha
Ram V Anantha
SXStacey Xu
Stacey Xu
MDMarisa Donnelly
Marisa Donnelly
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar
TMTina Mele
Tina Mele
The lack of a reliable scoring system that predicts the development of septic shock and death precludes comparison of disease and/or treatment outcomes in animal models of sepsis. We developed a murine sepsis score (MSS) that evaluates seven clinical variables, and sought to assess its validity and reliability in an experimental mouse model of polymicrobial sepsis.

20 June 2017 in PLOS Biology
Verified
Journal Article
Open access
PDF file
CSChristopher R. Shaler
Christopher R. Shaler
JCJoshua Choi
Joshua Choi
PRPatrick T. Rudak
Patrick T. Rudak
AMArash Memarnejadian
Arash Memarnejadian
PSPeter A. Szabo
Peter A. Szabo
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar
Superantigens (SAgs) are potent exotoxins secreted by Staphylococcus aureus and Streptococcus pyogenes. They target a large fraction of T cell pools to set in motion a “cytokine storm” with severe and sometimes life-threatening consequences typically encountered in toxic shock syndrome (TSS). Given the rapidity with which TSS develops, designing timely and truly targeted therapies for this syndrome requires identification of key mediators of the cytokine storm’s initial wave. Equally important, early host responses to SAgs can be accompanied or followed by a state of immunosuppression, which in turn jeopardizes the host’s ability to combat and clear infections. Unlike in mouse models, the mechanisms underlying SAg-associated immunosuppression in humans are ill-defined. In this work, we have identified a population of innate-like T cells, called mucosa-associated invariant T (MAIT) cells, as the most powerful source of pro-inflammatory cytokines after exposure to SAgs. We have utilized primary human peripheral blood and hepatic mononuclear cells, mouse MAIT hybridoma lines, HLA-DR4-transgenic mice, MAIThighHLA-DR4+ bone marrow chimeras, and humanized NOD-scid IL-2Rγnull mice to demonstrate for the first time that: i) mouse and human MAIT cells are hyperresponsive to SAgs, typified by staphylococcal enterotoxin B (SEB); ii) the human MAIT cell response to SEB is rapid and far greater in magnitude than that launched by unfractionated conventional T, invariant natural killer T (iNKT) or γδ T cells, and is characterized by production of interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2, but not IL-17A; iii) high-affinity MHC class II interaction with SAgs, but not MHC-related protein 1 (MR1) participation, is required for MAIT cell activation; iv) MAIT cell responses to SEB can occur in a T cell receptor (TCR) Vβ–specific manner but are largely contributed by IL-12 and IL-18; v) as MAIT cells are primed by SAgs, they also begin to develop a molecular signature consistent with exhaustion and failure to participate in antimicrobial defense. Accordingly, they upregulate lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and mucin-3 (TIM-3), and/or programmed cell death-1 (PD-1), and acquire an anergic phenotype that interferes with their cognate function against Klebsiella pneumoniae and Escherichia coli; vi) MAIT cell hyperactivation and anergy co-utilize a signaling pathway that is governed by p38 and MEK1/2. Collectively, our findings demonstrate a pathogenic, rather than protective, role for MAIT cells during infection. Furthermore, we propose a novel mechanism of SAg-associated immunosuppression in humans. MAIT cells may therefore provide an attractive therapeutic target for the management of both early and late phases of severe SAg-mediated illnesses. Superantigens (SAgs) are toxins produced by Staphylococcus aureus and Streptococcus pyogenes, microbes that are responsible for a multitude of infectious diseases and conditions. Once released, SAgs activate many immune cells, resulting in a massive inflammatory response that is often followed by a state of immunosuppression, a state that favors opportunistic infections. Using primary human cells as well as wild-type and genetically altered mice, we have now identified a subset of unconventional, innate-like T lymphocytes, called mucosa-associated invariant T (MAIT) cells, as one of the most powerful and quick-acting sources of inflammatory mediators in the aftermath of systemic exposure to SAgs. We also demonstrate that robust activation of MAIT cells by SAgs quickly leads to their exhaustion, and this exhaustion interferes with their ability to participate in antimicrobial host defense and contributes to the immunosuppressive state. Our findings thus define a pathogenic role for MAIT cells during Gram-positive bacterial infections and also uncover a novel mechanism of SAg-mediated immunosuppression. Accordingly, we propose that MAIT cells can be targeted for efficacious treatment of SAg-mediated illnesses.

29 May 2018 in Pathogens
Verified
Journal Article
Open access
PDF file
STStephen Tuffs
Stephen Tuffs
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar
JMJohn Mccormick
John Mccormick
Staphylococcal superantigens (SAgs) constitute a family of potent exotoxins secreted by Staphylococcus aureus and other select staphylococcal species. SAgs function to cross-link major histocompatibility complex (MHC) class II molecules with T cell receptors (TCRs) to stimulate the uncontrolled activation of T lymphocytes, potentially leading to severe human illnesses such as toxic shock syndrome. The ubiquity of SAgs in clinical S. aureus isolates suggests that they likely make an important contribution to the evolutionary fitness of S. aureus. Although the apparent redundancy of SAgs in S. aureus has not been explained, the high level of sequence diversity within this toxin family may allow for SAgs to recognize an assorted range of TCR and MHC class II molecules, as well as aid in the avoidance of humoral immunity. Herein, we outline the major diseases associated with the staphylococcal SAgs and how a dysregulated immune system may contribute to pathology. We then highlight recent research that considers the importance of SAgs in the pathogenesis of S. aureus infections, demonstrating that SAgs are more than simply an immunological diversion. We suggest that SAgs can act as targeted modulators that drive the immune response away from an effective response, and thus aid in S. aureus persistence.

9 August 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JZJoseph J. Zeppa
Joseph J. Zeppa
KKKatherine J. Kasper
Katherine J. Kasper
IMIvor Mohorovic
Ivor Mohorovic
DMDelfina M. Mazzuca
Delfina M. Mazzuca
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar
JMJohn Mccormick
John Mccormick
Significance: Superantigen toxins were defined over 25 years ago for their ability to activate T cells in a T-cell receptor β-chain variable domain-dependent manner. This “Vβ-specific” T-cell activation is the hallmark feature of the superantigen, and although these toxins can mediate dangerous human disease such as toxic shock syndrome, mechanisms that explain why bacteria produce superantigens have remained enigmatic. Herein, we provide evidence thatStreptococcus pyogenesutilizes superantigens to target functional, Vβ-specific T cells to promote a state of colonization providing a mechanism that helps explain why bacteria produce toxins that specifically activate T cells of the adaptive immune system. This work also implicates the superantigen exotoxins as potential vaccine candidates against this globally important, human-specific pathogen.

10 August 2017 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
CSChristopher R. Shaler
Christopher R. Shaler
MTMauro E. Tun-Abraham
Mauro E. Tun-Abraham
ASAnton I. Skaro
Anton I. Skaro
KKKhashayarsha Khazaie
Khashayarsha Khazaie
ACAlexandra Corbett
Alexandra Corbett
SHS.M. Mansour Haeryfar
S.M. Mansour Haeryfar